文献速递骨质疏松与代谢性骨病

每周一次特立帕肽注射序贯阿仑膦酸钠与单用阿仑膦酸钠治疗骨质疏松性骨折高风险患者的比较:日本骨质疏松干预试验-05最终结果

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
PubMed 文献 · Osteoporos Int · 2022-10-14

这项随机对照试验纳入骨折高风险的日本女性骨质疏松患者,比较每周一次皮下注射特立帕肽72周后序贯阿仑膦酸钠48周与单用阿仑膦酸钠120周的疗效。结果显示序贯治疗组形态学椎体骨折发生率显著低于单药组,率比为0.69(95%CI 0.54至0.88,P<0.01)。

要点

  • 序贯治疗组形态学椎体骨折年发生率为0.1020,单药组为0.1492。
  • 序贯治疗组与单药组形态学椎体骨折发生率率比为0.69(95%CI 0.54至0.88,P<0.01)。
  • 治疗72周后,无患者发生与研究药物相关的严重不良事件。

核心结论

  • 在骨折高风险的日本女性骨质疏松患者中,每周一次注射特立帕肽后序贯阿仑膦酸钠治疗较单用阿仑膦酸钠显著降低形态学椎体骨折发生率。

研究设计与样本

  • 前瞻性、随机、开放标签、盲法终点试验,纳入至少75岁、原发性骨质疏松且骨折高风险的日本女性。
  • 患者按1:1随机分配至序贯治疗组(每周一次皮下注射特立帕肽56.5μg共72周,随后阿仑膦酸钠治疗48周)或单用阿仑膦酸钠治疗120周组。
  • 最终分析主要终点为120周随访期间形态学椎体骨折的发生率。
  • 2014年10月至2020年6月期间,序贯治疗组入组505例,单药组入组506例;主要分析分别纳入489例和496例。

主要发现

  • 序贯治疗组120周随访期间形态学椎体骨折发生率为每627.5人年64例,年发生率0.1020;单药组为每844.2人年126例,年发生率0.1492。
  • 序贯治疗组较单药组形态学椎体骨折发生率率比为0.69(95%CI 0.54至0.88,P<0.01)。
  • 治疗72周后,无患者发生与研究药物相关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture. PURPOSE: To determine whether the anti-fracture efficacy of sequential therapy with teriparatide, followed by alendronate is superior to that of monotherapy with alendronate, a prospective, randomized, open-label, blinded-endpoint trial was performed. METHODS: Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture. Patients were randomly assigned (1:1) to receive the sequential therapy (once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks, followed by alendronate for 48 weeks) or monotherapy with alendronate for 120 weeks. The primary endpoint in the final analysis was the incidence of morphometric vertebral fracture during the 120-week follow-up period. RESULTS: Between October 2014 and June 2020, 505 patients in the sequential therapy group and 506 in the monotherapy group were enrolled. Of these, 489 and 496, respectively, were included in the main analysis. The incidence of morphometric vertebral fracture during the 120-week follow-up period in the sequential therapy group (64 per 627.5 person-years, annual incidence rate 0.1020) was significantly lower than that in the monotherapy group (126 per 844.2 person-years, annual incidence rate 0.1492), with a rate ratio of 0.69 (95% confidence interval 0.54 to 0.88, P < 0.01). After 72 weeks, no patient had a severe adverse event that was considered related to the study drug. CONCLUSION: Once-weekly injection of teriparatide, followed by alendronate resulted in a significantly lower incidence of morphometric vertebral fracture than alendronate monotherapy in women with osteoporosis who were at high risk of fracture. TRIAL REGISTRATION NUMBER, DATE OF REGISTRATION: jRCTs031180235 and UMIN000015573, March 12, 2019.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Mori S, Hagino H, Sugimoto T, et al. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int. 2022. PMID: 36239756. doi:10.1007/s00198-022-06570-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。